Loading…
MBX Biosciences, Inc. is projected to rise to $43.44 by 2027, a +36% move from its current price of $31.88. MBX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $30.57 | $31.87 | $33.24 | -0.02% |
| May 30 | $30.03 | $31.87 | $33.81 | -0.04% |
| May 31 | $29.63 | $31.86 | $34.26 | -0.06% |
| Jun 1 | $29.30 | $31.86 | $34.64 | -0.07% |
| Jun 2 | $29.00 | $31.85 | $34.98 | -0.09% |
| Jun 3 | $28.74 | $31.84 | $35.29 | -0.11% |
| Jun 4 | $28.50 | $31.84 | $35.57 | -0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $28.50 | $31.84 | $35.57 | -0.13% |
| Week 2 | $27.18 | $31.80 | $37.19 | -0.26% |
| Week 3 | $26.21 | $31.76 | $38.48 | -0.39% |
| Week 4 | $25.41 | $31.71 | $39.58 | -0.52% |
| Week 5 | $24.72 | $31.67 | $40.58 | -0.65% |
| Week 6 | $24.11 | $31.63 | $41.50 | -0.78% |
| Week 7 | $23.56 | $31.59 | $42.35 | -0.91% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX Biosciences operates in the healthcare space and focuses on peptide-based therapies targeting endocrine and metabolic conditions. The descriptions of its pipeline and development stages provide a snapshot of its clinical priorities and strategic focus.
MBX Biosciences, Inc. (MBX) currently trades at $31.85 per share and has a market capitalization of $1.52B, ranking 2218. These figures place MBX within a broad, mid-cap segment of the market while reflecting its development-stage profile.
Technically, the stock shows a neutral near-term posture with RSI at 50. The SMA(50) is $31.62 and the SMA(200) is $26.77, framing a modestly constructive moving-average setup. Support is noted at $28.61 and resistance at $40.97, with a 30-day range of $23.74 to $42.72, indicating substantial short-term volatility.
Forecasts imply a neutral to bullish price trajectory over time. The 2026 forecast has an average of $31.85 with a min of $26.92 and a max of $45.60, and a neutral sentiment. From 2027 onward, the projections become more bullish, with annual averages climbing toward higher targets and rising ROIs across the horizon (e.g., 2027 avg $45.23, 2028 avg $49.48, 2030 avg $53.24, 2040 avg $125.70, 2050 avg $184.96).
A major floor 32.7% below — a decisive break under it would weaken the trend.
The nearest floor, 10.3% below — buyers have tended to step in here.
The nearest ceiling, 28.5% above — a clean break opens room to run.
A major ceiling 44.8% above — clearing it would confirm fresh momentum.
Key MBX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MBX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $31.74 | Buy | $31.91 | Sell |
| MA 10 | $32.54 | Sell | $32.39 | Sell |
| MA 20 | $32.89 | Sell | $32.67 | Sell |
| MA 50 | $31.73 | Buy | $32.46 | Sell |
| MA 100 | $33.47 | Sell | $31.42 | Buy |
| MA 200 | $26.97 | Buy | $27.98 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.48 | Neutral |
| Stoch RSI (14) | 13.72 | Buy |
| CCI (20) | -23.95 | Neutral |
| Williams %R (14) | -85.91 | Info |
| MACD (12,26,9) | -0.39 | Sell |
| ROC (12) | -22.18 | Sell |
| Bollinger %B (20,2) | 0.43 | Neutral |
| Stochastic %K (14) | 14.09 | Buy |
| TRIX (15) | 0.16 | Buy |
| Awesome (5,34) | -1.03 | Sell |
| Ultimate (7,14,28) | 45.22 | Neutral |
| Momentum (10) | -5.10 | Sell |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 31.71 | Buy |
| ADX (14) | 13.00 | Neutral |
| ATR (14) | 1.15 | Info |
The 30-day technical picture shows a neutral sentiment with RSI(14) at 50. The market sits around the key moving averages, with SMA(50) at $31.62 and SMA(200) at $26.77. A defined support level sits at $28.61 and a resistance at $40.97, outlining a clear near-term trading range.
The 30-day price range is $23.74 to $42.72, illustrating meaningful volatility within the month while price action remains bounded between support and resistance levels.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $26.92 | $31.88 | $44.63 | 0% | Neutral | |
| $32.67 | $43.44 | $62.11 | +36% | Bullish | |
| $34.04 | $47.31 | $71.15 | +48% | Bullish | |
| $33.44 | $48.27 | $75.54 | +51% | Bullish | |
| $33.76 | $50.40 | $81.54 | +58% | Bullish | |
| $31.15 | $47.99 | $79.91 | +51% | Bullish | |
| $32.12 | $50.98 | $87.09 | +60% | Bullish | |
| $38.61 | $63.04 | $110.22 | +98% | Bullish | |
| $45.19 | $75.81 | $135.40 | +138% | Bullish | |
| $46.77 | $80.54 | $146.70 | +153% | Bullish | |
| $56.73 | $110.56 | $218.43 | +247% | Bullish | |
| $74.70 | $166.00 | $368.33 | +421% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $26.92 | $31.88 | $37.37 | +0.00% |
| June 2026 | $25.53 | $30.33 | $37.15 | -4.85% |
| July 2026 | $26.03 | $31.34 | $39.17 | +3.32% |
| August 2026 | $26.09 | $31.74 | $40.28 | +1.26% |
| September 2026 | $25.00 | $30.67 | $39.42 | -3.36% |
| October 2026 | $25.49 | $31.51 | $40.96 | +2.75% |
| November 2026 | $27.06 | $33.69 | $44.22 | +6.91% |
| December 2026 | $26.88 | $33.69 | $44.63 | +0.01% |
Click any year to see its month-by-month MBX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The MBX price prediction for 2026 points to an average of $31.88 (low $26.92, high $44.63) — a potential gain of 0% on today's $31.88. Price action looks broadly range-bound.
In 2027, MBX is projected to trade between $32.67 and $62.11, averaging $43.44 — a potential gain of +36% from today's $31.88. That is up +36% on the projected 2026 average. Buyers look set to stay in control over this stretch.
MBX Biosciences, Inc.'s 2028 outlook centres on $47.31, within a $34.04 to $71.15 range. That is up +9% on the projected 2027 average. That marks a +48% change versus current levels. Momentum favours further upside here.
By 2029, MBX could reach as high as $75.54, with a base case around $48.27 and support toward $33.44 — roughly +51% from $31.88. Buyers look set to stay in control over this stretch.
Expect MBX to range from $33.76 to $81.54 through 2030. The $50.40 average target implies a +58% move from current prices. That is up +4% on the projected 2029 average. Momentum favours further upside here.
The MBX price prediction for 2031 points to an average of $47.99 (low $31.15, high $79.91) — a potential gain of +51% on today's $31.88. Buyers look set to stay in control over this stretch.
In 2032, MBX is projected to trade between $32.12 and $87.09, averaging $50.98 — a potential gain of +60% from today's $31.88. That is up +6% on the projected 2031 average. Momentum favours further upside here.
MBX Biosciences, Inc.'s 2033 outlook centres on $63.04, within a $38.61 to $110.22 range. That is up +24% on the projected 2032 average. That marks a +98% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, MBX could reach as high as $135.40, with a base case around $75.81 and support toward $45.19 — roughly +138% from $31.88. Momentum favours further upside here.
Expect MBX to range from $46.77 to $146.70 through 2035. The $80.54 average target implies a +153% move from current prices. That is up +6% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The MBX price prediction for 2040 points to an average of $110.56 (low $56.73, high $218.43) — a potential gain of +247% on today's $31.88. Momentum favours further upside here.
In 2050, MBX is projected to trade between $74.70 and $368.33, averaging $166.00 — a potential gain of +421% from today's $31.88. That is up +50% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in MBX today (≈ 31.367629 MBX) could be worth
$5,207.1
+$4,207.1 (+421%) by 2050 · US Dollar
Based on the average projected MBX price of $166 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MBXwould be worth at today's price.
$1,000 invested in MBX on May 27, 2025 (≈ 79.365077 MBX) would be worth
$2,530.16
+$1,530.16 (+153.0%) today · 2.53× · US Dollar
Based on a MBX entry price of $12.6 vs. today's $31.88.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $31.43 | $1,014.32 | +1.4% |
| 1 month ago | $31.97 | $997.18 | -0.3% |
| 3 months ago | $35.04 | $909.82 | -9.0% |
| 6 months ago | $34.49 | $924.33 | -7.6% |
| 1 year ago | $12.6 | $2,530.16 | +153.0% |
| All time (1.7y) ago | $23.65 | $1,347.99 | +34.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MBX forecast.
Our base-case forecast reaches $64.00 around 2034.
Implied market cap at $64.00: $3.05B
The multi-year forecast depicts a bullish trajectory after a neutral start in 2026. The 2026 average target is $31.85, with a max of $45.60 and a min of $26.92, yielding a 0% ROI and neutral sentiment. From 2027 onward, the outlook grows more ambitious, with 2027 average $45.23 and a max of $65.49, and a 2027 ROI of 42%.
By 2028, the average rises to $49.48 (max $75.55, ROI 55.3%), and 2029 shows an average of $49.99 (max $79.55, ROI 57%).
In 2030 the forecast calls for an average of $53.24 with a max of $87.72 and a min of $34.96, delivering a 67.2% ROI and a bullish sentiment. The 2031–2032 period continues the uptrend with 2031 average $50.70 and 2032 average $54.17 (maxes $86.07 and $94.45 respectively, both bullish). By 2033 the average is $70.21 (max $125.43) and by 2034 it is $83.69 (max $152.84), continuing a strong upward arc through the mid-2030s.
The long-range view shows further gains with 2035 average $87.49 (max $163.07, ROI 174.7%), 2040 average $125.70 (max $254.91, ROI 294.7%), and 2050 average $184.96 (max $422.89, ROI 480.7%). These figures illustrate a persistent bullish tilt, tempered by the usual uncertainty inherent in long-range forecasts.
Note: These targets are estimates, not guarantees, and carry inherent uncertainty. The outcomes depend on many factors, including clinical progression, regulatory outcomes, and market dynamics.
Tap a question to reveal the answer.
In 2030, the average target is $53.24, with a min of $34.96 and a max of $87.72. The forecast shows an ROI of 67.2% and a bullish sentiment for that year.
The forecast shows a bullish trajectory from 2027 onward with higher average targets and positive ROIs (e.g., 2027 avg $45.23, ROI 42; 2030 avg $53.24, ROI 67.2; 2040 avg $125.70, ROI 294.7; 2050 avg $184.96, ROI 480.7). The 2026 outlook is neutral with an average of $31.85 and ROI of 0. These are estimates, not guarantees.
The forecast includes years with higher targets that exceed $100. For example, 2033 has a max of $125.43 and 2034 has a max of $152.84, indicating the potential to surpass $100 in the forecast horizon.
The 30-day price range is $23.74 to $42.72.
In 2040, the average target is $125.70, with a max of $254.91 and a min of $61.63, reflecting a bullish long-term outlook and a 294.7% ROI.
MBX Biosciences, Inc. Community Discussion
0Share your MBX Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.